S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13

Harvard Bioscience Stock Forecast, Price & News

+0.10 (+2.78%)
(As of 07/1/2022 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
201,392 shs
Average Volume
237,770 shs
Market Capitalization
$152.59 million
P/E Ratio
Dividend Yield
Price Target

Harvard Bioscience Stock Forecast (MarketRank)

Analyst Rating
Short Interest
5.06% of Float Sold Short
Dividend Strength
Upright™ Environmental Score
News Sentiment
0.04mentions of Harvard Bioscience in the last 14 days
Based on 12 Articles This Week
Insider Trading
Acquiring Shares
$147.40 K Bought Last Quarter
Proj. Earnings Growth
From $0.26 to $0.32 Per Share

Overall MarketRank

MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.

1.55 out of 5 stars

Computer And Technology Sector

468th out of 937 stocks

Analytical Instruments Industry

16th out of 33 stocks

30 days | 90 days | 365 days | Advanced Chart

Receive HBIO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Harvard Bioscience and its competitors with MarketBeat's FREE daily newsletter.

Harvard Bioscience logo

About Harvard Bioscience (NASDAQ:HBIO)

Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services that enables fundamental research, discovery, and pre-clinical testing for drug development in the United States and internationally. The company offers cellular and molecular technology instruments, such as syringe and peristaltic pump products, as well as a range of instruments and accessories for tissue and organ-based lab research, including surgical products, infusion systems, and behavior research systems; and spectrophotometers, microplate readers, amino acid analyzers, gel electrophoresis equipment, and electroporation and electrofusion instruments. It also engages in the development and manufacture of precision scientific measuring instrumentation and equipment, which cover data acquisition systems with custom amplifier configurations for cellular analysis, micro electrode array solutions for in vivo recordings, and vitro-systems for extracellular recordings; and offers preclinical products. The company markets its products through sales organizations, websites, catalogs, and distributors to research scientists in pharmaceutical and biotechnology companies, universities, hospitals, and government laboratories, as well as to contract research organizations, academic labs, and government researchers. It primarily sells its products under Harvard Apparatus, DSI, Ponemah, Buxco, Biochrom, BTX, and MCS brand names. The company was founded in 1901 and is headquartered in Holliston, Massachusetts.

HBIO Stock News Headlines

See More Headlines

Industry, Sector and Symbol

Analytical instruments
Life Sciences Tools & Services
Current Symbol
Year Founded

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End


Net Income
$-290 thousand
Pretax Margin


Sales & Book Value

Annual Sales
$118.90 million
Cash Flow
$0.37 per share
Book Value
$2.04 per share


Free Float
Market Cap
$152.59 million

Harvard Bioscience Frequently Asked Questions

How has Harvard Bioscience's stock price performed in 2022?

Harvard Bioscience's stock was trading at $7.05 at the start of the year. Since then, HBIO shares have decreased by 47.5% and is now trading at $3.70.
View the best growth stocks for 2022 here

When is Harvard Bioscience's next earnings date?

Harvard Bioscience is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022.
View our earnings forecast for Harvard Bioscience

How were Harvard Bioscience's earnings last quarter?

Harvard Bioscience, Inc. (NASDAQ:HBIO) released its quarterly earnings results on Wednesday, May, 4th. The medical instruments supplier reported $0.02 earnings per share for the quarter, missing analysts' consensus estimates of $0.03 by $0.01. The medical instruments supplier earned $28.78 million during the quarter, compared to analysts' expectations of $29.10 million. Harvard Bioscience had a negative net margin of 5.38% and a positive trailing twelve-month return on equity of 9.06%. During the same quarter in the previous year, the company earned $0.03 EPS.
View Harvard Bioscience's earnings history

What guidance has Harvard Bioscience issued on next quarter's earnings?

Harvard Bioscience issued an update on its FY 2022 earnings guidance on Monday, May, 9th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $128.42 million-$134.36 million, compared to the consensus revenue estimate of $131.18 million.

Who are Harvard Bioscience's key executives?

Harvard Bioscience's management team includes the following people:
  • Mr. James W. Green, Pres, CEO & Chairman (Age 64, Pay $1.02M)
  • Mr. Michael A. Rossi, Chief Financial Officer (Age 48, Pay $478.75k)
  • Mr. Kenneth Fletcher Olson, Exec. Officer (Age 60, Pay $414.31k)
  • Mr. Jacques Coumans Ph.D., Chief Marketing Officer
  • David Sirois, Director of Corp. Accounting & SEC Reporting

What other stocks do shareholders of Harvard Bioscience own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Harvard Bioscience investors own include Bank of Hawaii (BOH), InterDigital (IDCC), STAG Industrial (STAG), NVIDIA (NVDA), LightPath Technologies (LPTH), Micron Technology (MU), Nokia Oyj (NOK), Evoke Pharma (EVOK), General Electric (GE) and Gilead Sciences (GILD).

What is Harvard Bioscience's stock symbol?

Harvard Bioscience trades on the NASDAQ under the ticker symbol "HBIO."

How do I buy shares of Harvard Bioscience?

Shares of HBIO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Harvard Bioscience's stock price today?

One share of HBIO stock can currently be purchased for approximately $3.70.

How much money does Harvard Bioscience make?

Harvard Bioscience (NASDAQ:HBIO) has a market capitalization of $152.59 million and generates $118.90 million in revenue each year. The medical instruments supplier earns $-290 thousand in net income (profit) each year or ($0.160010) on an earnings per share basis.

How many employees does Harvard Bioscience have?

Harvard Bioscience employs 475 workers across the globe.

How can I contact Harvard Bioscience?

Harvard Bioscience's mailing address is 84 OCTOBER HILL RD, HOLLISTON MA, 01746. The official website for Harvard Bioscience is www.harvardbioscience.com. The medical instruments supplier can be reached via phone at (508) 893-8999, via email at [email protected], or via fax at 508-429-5732.

This page (NASDAQ:HBIO) was last updated on 7/2/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.